Clinical-stage cancer immunotherapy company Compugen Ltd (Nasdaq: CGEN) (TASE: CGEN) on Monday announced the first patient dosing in Sub-trial 1 of MAIA-ovarian, a global adaptive platform trial evaluating COM701 as maintenance therapy in relapsed platinum-sensitive ovarian cancer. COM701 is a potential first-in-class anti-PVRIG antibody developed using Compugen's AI/ML-powered Unigen discovery platform.

Sub-trial 1 is a randomised, double-blind, placebo-controlled study enrolling 60 patients in a 2:1 ratio to receive COM701 or placebo. The trial aims to determine whether COM701 delays disease progression and further establish its safety in this setting. Interim analysis is planned for H2 2026, with future sub-trials expected to explore COM701 in combination therapies.

Compugen's immuno-oncology pipeline includes COM701 and COM902, its anti-TIGIT antibody, both in Phase 1 development. Its TIGIT component is also part of AstraZeneca's Phase 3 bispecific antibody rilvegostomig. Compugen also has a partnered IL-18BP program, GS-0321, in Phase 1 with Gilead.

Headquartered in Israel with US operations, Compugen is advancing a pipeline of precision immunotherapies targeting novel immune checkpoints.